Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Altus Prices $105M IPO; Funds Earmarked For Phase III Study

Jan. 27, 2006

By Jennifer Boggs

Altus Prices $105M IPO; Funds Earmarked For Phase III Study

Jan. 27, 2006

By Jennifer Boggs

Targeted Genetics Trims Staff, Cash Burn To Focus On Clinic

Jan. 26, 2006

By Jennifer Boggs

Targeted Genetics Trims Staff, Cash Burn To Focus On Clinic

Jan. 26, 2006

By Jennifer Boggs

VC Financing Steady In 2005; Investors Favoring Late Stage

Jan. 25, 2006

By Jennifer Boggs

Curis, Genentech Stumble In Phase I Trial Of Cancer Drug

Jan. 25, 2006

By Jennifer Boggs

Curis, Genentech Stumble In Phase I Trial Of Cancer Drug

Jan. 25, 2006

By Jennifer Boggs

VC Financing Steady In 2005; Investors Favoring Late Stage

Jan. 25, 2006

By Jennifer Boggs

Young Firm Novelix Growing Portfolio Via USC In-Licensing

Jan. 24, 2006

By Jennifer Boggs

Young Firm Novelix Growing Portfolio Via USC In-Licensing

Jan. 24, 2006

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.